17,406 Shares in Acceleron Pharma (XLRN) Acquired by MetLife Investment Advisors LLC

MetLife Investment Advisors LLC purchased a new stake in shares of Acceleron Pharma (NASDAQ:XLRN) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 17,406 shares of the biopharmaceutical company’s stock, valued at approximately $739,000.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. BlackRock Inc. boosted its position in Acceleron Pharma by 10.1% during the 4th quarter. BlackRock Inc. now owns 4,732,135 shares of the biopharmaceutical company’s stock valued at $200,832,000 after buying an additional 434,123 shares during the period. Farallon Capital Management LLC boosted its position in Acceleron Pharma by 13.0% during the 4th quarter. Farallon Capital Management LLC now owns 1,088,000 shares of the biopharmaceutical company’s stock valued at $46,175,000 after buying an additional 125,000 shares during the period. Carillon Tower Advisers Inc. purchased a new stake in Acceleron Pharma during the 4th quarter valued at $40,014,000. Artal Group S.A. boosted its position in Acceleron Pharma by 7.1% during the 4th quarter. Artal Group S.A. now owns 750,000 shares of the biopharmaceutical company’s stock valued at $31,830,000 after buying an additional 50,000 shares during the period. Finally, Sectoral Asset Management Inc boosted its position in Acceleron Pharma by 17.8% during the 4th quarter. Sectoral Asset Management Inc now owns 712,356 shares of the biopharmaceutical company’s stock valued at $30,232,000 after buying an additional 107,399 shares during the period. 88.23% of the stock is owned by institutional investors and hedge funds.

How to Become a New Pot Stock Millionaire

In related news, EVP Matthew L. Sherman sold 4,600 shares of Acceleron Pharma stock in a transaction dated Tuesday, April 3rd. The shares were sold at an average price of $38.43, for a total transaction of $176,778.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Richard F. Pops sold 37,500 shares of Acceleron Pharma stock in a transaction dated Tuesday, March 6th. The shares were sold at an average price of $41.42, for a total transaction of $1,553,250.00. Following the transaction, the director now directly owns 68,750 shares of the company’s stock, valued at $2,847,625. The disclosure for this sale can be found here. Over the last three months, insiders have sold 47,304 shares of company stock valued at $1,930,062. 3.90% of the stock is currently owned by corporate insiders.



Several equities research analysts have weighed in on the stock. Citigroup increased their price target on shares of Acceleron Pharma from $44.00 to $63.00 and gave the company a “positive” rating in a research report on Thursday, March 1st. Oppenheimer reissued a “hold” rating on shares of Acceleron Pharma in a research report on Monday, January 8th. Barclays increased their price target on shares of Acceleron Pharma from $50.00 to $54.00 and gave the company an “overweight” rating in a research report on Wednesday, February 28th. BidaskClub raised shares of Acceleron Pharma from a “hold” rating to a “buy” rating in a research report on Wednesday, December 27th. Finally, JPMorgan Chase raised shares of Acceleron Pharma from a “neutral” rating to an “overweight” rating and set a $33.00 price target for the company in a research report on Monday, February 26th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and twelve have given a buy rating to the stock. Acceleron Pharma has a consensus rating of “Buy” and an average price target of $47.06.

NASDAQ:XLRN opened at $37.43 on Friday. Acceleron Pharma has a 12 month low of $24.37 and a 12 month high of $46.93. The stock has a market capitalization of $1,734.10, a PE ratio of -13.97 and a beta of 1.43.

Acceleron Pharma (NASDAQ:XLRN) last posted its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.62) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by ($0.02). Acceleron Pharma had a negative return on equity of 38.71% and a negative net margin of 804.49%. The company had revenue of $3.71 million during the quarter, compared to analysts’ expectations of $3.39 million. research analysts predict that Acceleron Pharma will post -2.5 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “17,406 Shares in Acceleron Pharma (XLRN) Acquired by MetLife Investment Advisors LLC” was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://stocknewstimes.com/2018/04/15/17406-shares-in-acceleron-pharma-xlrn-acquired-by-metlife-investment-advisors-llc.html.

Acceleron Pharma Company Profile

Acceleron Pharma Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis.

Want to see what other hedge funds are holding XLRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Acceleron Pharma (NASDAQ:XLRN).

Institutional Ownership by Quarter for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply